menu
    • menu
    [{"orgOrder":0,"company":"Irvine School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Irvine School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Irvine School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Irvine School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"ACRO Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Collagen Ophthalmic Matrix","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"ACRO Biomedical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ACRO Biomedical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ACRO Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"GelMEDIX","sponsor":"HTL Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Hyaluronic Acid","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"GelMEDIX","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"GelMEDIX \/ HTL Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"GelMEDIX \/ HTL Biotechnology"},{"orgOrder":0,"company":"Eyenovia","sponsor":"SGN Nanopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Eyenovia \/ SGN Nanopharma","highestDevelopmentStatusID":"1","companyTruncated":"Eyenovia \/ SGN Nanopharma"},{"orgOrder":0,"company":"Selagine","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"SLG-100","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Selagine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Selagine \/ Grifols International","highestDevelopmentStatusID":"1","companyTruncated":"Selagine \/ Grifols International"},{"orgOrder":0,"company":"Re-Vana Therapeutics","sponsor":"Visionary Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Re-Vana Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"Re-Vana Therapeutics \/ Visionary Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Re-Vana Therapeutics \/ Visionary Ventures"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novelty Nobility","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GC Biopharma \/ Novelty Nobility","highestDevelopmentStatusID":"1","companyTruncated":"GC Biopharma \/ Novelty Nobility"},{"orgOrder":0,"company":"Ikarovec","sponsor":"Rentschler Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ikarovec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ikarovec \/ Rentschler Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Ikarovec \/ Rentschler Biopharma"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Adeno-associated Virus Vector","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"4D Molecular Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Ikarovec","sponsor":"UKi2S","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ikarovec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ikarovec \/ UKi2S","highestDevelopmentStatusID":"1","companyTruncated":"Ikarovec \/ UKi2S"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"PMC-403","moa":"Tie2","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ PharmAbcine","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ PharmAbcine"},{"orgOrder":0,"company":"Pharmathen SA","sponsor":"Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GREECE","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Pharmathen SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmathen SA \/ Partners Group","highestDevelopmentStatusID":"1","companyTruncated":"Pharmathen SA \/ Partners Group"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Horama Sa","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"HORA-001","moa":"CRB1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leiden University Medical Center \/ Horama Sa","highestDevelopmentStatusID":"1","companyTruncated":"Leiden University Medical Center \/ Horama Sa"},{"orgOrder":0,"company":"LGC Group GB","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"OLX301D","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"LGC Group GB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LGC Group GB \/ OliX Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"LGC Group GB \/ OliX Pharmaceutical"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tetra BioPharma \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pharmathen SA

                            Greece
                            euroPLX 88 Lisbon
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Partners Group

                            Deal Size : $1,900.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Partners Group to Acquire Pharmathen, a Leading European Pharmaceutical Company, from BC Partners

                            Details : Partners Group to Acquire Pharmathen, a Leading European Pharmaceutical Company, from BC Partners

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 19, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Partners Group

                            Deal Size : $1,900.0 million

                            Deal Type : Acquisition

                            Pharmathen

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GC Biopharma

                            South Korea arrow
                            German Wound Congress
                            Not Confirmed

                            GC Biopharma

                            South Korea arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Novelty Nobility

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GC Biopharma, Novelty Nobility Partner on Geographic Atrophy R&D

                            Details : Under the agreement terms, GC and Novelty will partner to jointly R&D antibody-based protein therapeutics for geographic atrophy, supporting all stages of the drug development lifecycle.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 28, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Novelty Nobility

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eyenovia

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Eyenovia

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : SGN Nanopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Eyenovia and SGN Nanopharma Announce Collaboration for Chronic Dry Eye Disease Treatment

                            Details : The companies will work to develop SGN’s MNP platform-based Cyclosporine formulation for use with Eyenovia’s Optejet dispenser for treatment of chronic dry eye disease.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            July 30, 2024

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : SGN Nanopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            4D Molecular Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            4D Molecular Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adeno-associated Virus Vector

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Astellas Pharma

                            Deal Size : $962.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitr...

                            Details : Astellas gains rights to utilize the intravitreal retinotropic R100 adeno-associated virus vector invented by 4DMT for one genetic target implicated in rare monogenic ophthalmic diseases, with options to add up to two additional targets implicated for th...

                            Product Name : R100

                            Product Type : Other Large Molecule

                            Upfront Cash : $20.0 million

                            October 07, 2023

                            Lead Product(s) : Adeno-associated Virus Vector

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Astellas Pharma

                            Deal Size : $962.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Selagine

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Selagine

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SLG-100

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Grifols International

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglo...

                            Details : Grifols will develop and commercialise immunoglobulin eye drops, SLG-100, for dry eye disease. An immunoglobulin eye drop is a biologic drug that contains naturally occurring functional antibodies generated from human plasma collected from thousands of h...

                            Product Name : SLG-100

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 03, 2023

                            Lead Product(s) : SLG-100

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Grifols International

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ikarovec

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed

                            Ikarovec

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Rentschler Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Rentschler Biopharma Joins Forces with Ikarovec to Accelerate Novel Gene Therapies for Treatment of Ophthalmic...

                            Details : Under the agreement, Rentschler Biopharma’s ATMP site will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel AAV-based therapy for the treatment of geographic atrophy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 06, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Rentschler Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            GelMEDIX

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            GelMEDIX

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Hyaluronic Acid

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : HTL Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            HTL Announces Its Incubator's Equity Investment In GelMEDIX, An Early-Stage Biotech Aiming At Revolutionizing ...

                            Details : This investment supports development of the GelMEDIX platform, which enables the delivery of therapeutics from small molecules to cell and gene therapies. HTL will produce methacrylate hyaluronic acid, a key component for specific parameters across the G...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 03, 2022

                            Lead Product(s) : Undisclosed,Hyaluronic Acid

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : HTL Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Re-Vana Therapeutics

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed

                            Re-Vana Therapeutics

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Visionary Ventures

                            Deal Size : $11.9 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Re-vana Therapeutics Raises $11.9 Million In Series A Financing

                            Details : The proceeds will advance the development of Re-Vana’s novel and proprietary photo-crosslinked EyeLief®, EyeLief-SD™ and OcuLief® biodegradable drug delivery technologies and will enable expansion of the company’s operations and development teams...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 12, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Visionary Ventures

                            Deal Size : $11.9 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Irvine School of Medicine

                            Country arrow
                            German Wound Congress
                            Not Confirmed

                            Irvine School of Medicine

                            Country arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Study by Irvine School of Medicine finds Antidepressant Drug Effective in Treating "Lazy Eye" in Adults

                            Details : The research team showed that ketamine down-regulates NRG1 expression in PV inhibitory cells, resulting in sustained cortical disinhibition to enhance cortical plasticity in adult visual cortex.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            September 30, 2020

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Samsung Biologics

                            South Korea arrow
                            German Wound Congress
                            Not Confirmed

                            Samsung Biologics

                            South Korea arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PMC-403

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : PharmAbcine

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            PharmAbcine Expands Partnership with Samsung Biologics for PMC-403

                            Details : Samsung will provide CDO services from cell line development, process development, cGMP clinical manufacturing to IND filing support for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat ne...

                            Product Name : PMC-403

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            September 21, 2020

                            Lead Product(s) : PMC-403

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : PharmAbcine

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth